UA97976C2 - 4'-о-замещенные изоиндолиновые производные и содержащие их композиции, и способы их применения - Google Patents

4'-о-замещенные изоиндолиновые производные и содержащие их композиции, и способы их применения

Info

Publication number
UA97976C2
UA97976C2 UAA200910592A UAA200910592A UA97976C2 UA 97976 C2 UA97976 C2 UA 97976C2 UA A200910592 A UAA200910592 A UA A200910592A UA A200910592 A UAA200910592 A UA A200910592A UA 97976 C2 UA97976 C2 UA 97976C2
Authority
UA
Ukraine
Prior art keywords
methods
compositions
same
substituted isoindoline
isoindoline derivatives
Prior art date
Application number
UAA200910592A
Other languages
English (en)
Ukrainian (uk)
Inventor
Александэр Л. Рачэлмэн
Джордж В. Мюллер
Хон-Вах МАН
Original Assignee
Селджин Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39719168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97976(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селджин Корпорэйшн filed Critical Селджин Корпорэйшн
Publication of UA97976C2 publication Critical patent/UA97976C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)

Abstract

Данное изобретение касается 4’-O-замещенных изоиндолиновых соединений, их фармацевтически приемлемых солей, сольватов, клатратов, стереоизомеров и пролекарств.Данное изобретение также касается способов применения фармацевтических композиций данных соединений.
UAA200910592A 2007-03-20 2008-03-19 4'-о-замещенные изоиндолиновые производные и содержащие их композиции, и способы их применения UA97976C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91932307P 2007-03-20 2007-03-20
PCT/US2008/003602 WO2008115516A2 (en) 2007-03-20 2008-03-19 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same

Publications (1)

Publication Number Publication Date
UA97976C2 true UA97976C2 (ru) 2012-04-10

Family

ID=39719168

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200910592A UA97976C2 (ru) 2007-03-20 2008-03-19 4'-о-замещенные изоиндолиновые производные и содержащие их композиции, и способы их применения

Country Status (25)

Country Link
US (6) US8153659B2 (ru)
EP (2) EP2142534B1 (ru)
JP (4) JP2010522170A (ru)
KR (3) KR20090121400A (ru)
CN (2) CN103641814A (ru)
AR (1) AR065810A1 (ru)
AU (1) AU2008229383B2 (ru)
BR (1) BRPI0809011A8 (ru)
CA (1) CA2681633C (ru)
CL (1) CL2008000805A1 (ru)
CO (1) CO6231033A2 (ru)
CR (2) CR11036A (ru)
EC (1) ECSP099663A (ru)
ES (2) ES2734253T3 (ru)
IL (1) IL200990A (ru)
MX (1) MX2009010082A (ru)
MY (1) MY180812A (ru)
NI (1) NI200900170A (ru)
NZ (2) NZ579890A (ru)
PE (1) PE20081894A1 (ru)
RU (1) RU2471794C2 (ru)
UA (1) UA97976C2 (ru)
UY (1) UY30977A1 (ru)
WO (1) WO2008115516A2 (ru)
ZA (1) ZA200906497B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
EP1924250B1 (en) * 2004-12-01 2017-01-04 Celgene Corporation Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders
AR065810A1 (es) * 2007-03-20 2009-07-01 Celgene Corp Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
WO2009085234A2 (en) 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
AU2016203826B2 (en) * 2010-02-11 2018-05-17 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2013245487B2 (en) * 2010-02-11 2016-03-10 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
PT3202460T (pt) * 2010-02-11 2019-08-05 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2839438C (en) * 2011-06-15 2020-08-04 Nono Inc. Agents and methods for treating ischemic and other diseases
CN102731851B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 一种耐油橡胶
CN102731853B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 耐油橡胶
CN102731850B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 耐油耐磨橡胶
ES2755748T3 (es) * 2012-07-27 2020-04-23 Celgene Corp Procedimientos para preparar compuestos de isoindolin-1,3-diona
JP6250671B2 (ja) 2012-08-09 2017-12-20 セルジーン コーポレイション 免疫関連及び炎症性疾患の治療
TWI723266B (zh) * 2012-08-09 2021-04-01 美商西建公司 利用3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)六氫吡啶-2,6-二酮治療癌症之方法
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
IN2015DN00845A (ru) 2012-08-09 2015-06-12 Celgene Corp
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US20140314752A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
EP3145513B1 (en) 2014-05-19 2023-11-15 Celgene Corporation 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
PL3214081T3 (pl) * 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
US10159665B2 (en) 2016-03-23 2018-12-25 Louis Habash Preventing amyloid plaque formation by treating a human subject with a nitroxide
WO2017165572A1 (en) * 2016-03-23 2017-09-28 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
JP7048106B2 (ja) * 2016-12-16 2022-04-05 カンプ・バイオファーマスーティカルズ、リミテッド 組み合わせ、その用途及び処置方法
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CA3096790C (en) * 2018-04-09 2024-03-19 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
HRP20231199T1 (hr) 2018-04-23 2024-01-19 Celgene Corporation Supstituirani spojevi 4-aminoizoindolin-1,3-diona i njihova upotreba za liječenje limfoma
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
US11192877B2 (en) * 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7168773B2 (ja) * 2018-09-30 2022-11-09 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
CN112839658A (zh) 2018-10-01 2021-05-25 细胞基因公司 用于治疗癌症的组合疗法
US20220001018A1 (en) * 2018-11-01 2022-01-06 Northwestern University Targeting pleckstrin-2 for treating cancer
AU2019392231B2 (en) 2018-12-06 2022-10-20 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
WO2020172418A1 (en) * 2019-02-22 2020-08-27 Elkem Silicones USA Corp. Drug delivery silicone compositon to improve active ingredient elution
CN111747924B (zh) * 2019-03-29 2023-11-10 华东师范大学 一类来那度胺/泊马度胺类似物及其应用
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
JP2022534650A (ja) * 2019-05-31 2022-08-03 海思科医▲薬▼有限公司 Ｂｔｋ阻害薬環誘導体、その調製方法及びその医薬品適用
CA3169011A1 (en) * 2020-02-25 2021-09-02 Xiaobao Yang Glutarimide skeleton-based compounds and uses thereof
AU2021255966A1 (en) * 2020-04-17 2022-11-17 Escient Pharmaceuticals, Inc. Modulators of mas-related G-protein receptor X4 and related products and methods
BR112023000817A2 (pt) * 2020-07-20 2023-02-07 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo
WO2022148358A1 (zh) * 2021-01-05 2022-07-14 江苏恒瑞医药股份有限公司 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
TW202340167A (zh) * 2022-01-19 2023-10-16 大陸商江蘇恒瑞醫藥股份有限公司 含硫異吲哚啉類衍生物的晶型
WO2024097932A1 (en) * 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Compounds and their use for treatment of hemoglobinopathies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
KR19980074060A (ko) * 1997-03-21 1998-11-05 김윤배 신규한 치환된 3,4-디알콕시페닐 유도체
BR9908811A (pt) * 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CN1867331B (zh) * 2003-09-17 2010-05-26 美国政府健康及人类服务部 作为TNF-α调节剂的沙利度胺类似物
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
EP1924250B1 (en) 2004-12-01 2017-01-04 Celgene Corporation Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders
BRPI0519287A2 (pt) * 2004-12-24 2009-01-06 Astrazeneca Ab derivados de amida
AR065810A1 (es) * 2007-03-20 2009-07-01 Celgene Corp Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.

Also Published As

Publication number Publication date
KR20150046384A (ko) 2015-04-29
US20180155316A1 (en) 2018-06-07
EP2142534A2 (en) 2010-01-13
ECSP099663A (es) 2009-10-30
US9181216B2 (en) 2015-11-10
PE20081894A1 (es) 2009-01-26
CR11036A (es) 2009-10-06
KR20090121400A (ko) 2009-11-25
US8614328B2 (en) 2013-12-24
BRPI0809011A2 (pt) 2014-09-16
WO2008115516A2 (en) 2008-09-25
WO2008115516A8 (en) 2008-12-31
AU2008229383B2 (en) 2013-09-05
US9920027B2 (en) 2018-03-20
UY30977A1 (es) 2008-10-31
ZA200906497B (en) 2010-11-24
JP2016065067A (ja) 2016-04-28
CA2681633C (en) 2018-01-09
JP2010522170A (ja) 2010-07-01
US20090004209A1 (en) 2009-01-01
IL200990A0 (en) 2010-05-17
WO2008115516A3 (en) 2008-11-13
BRPI0809011A8 (pt) 2019-01-15
EP2142534B1 (en) 2016-08-10
NZ579890A (en) 2012-05-25
AU2008229383A1 (en) 2008-09-25
JP6373818B2 (ja) 2018-08-15
KR20170093996A (ko) 2017-08-16
USRE46639E1 (en) 2017-12-19
JP6448726B2 (ja) 2019-01-09
AR065810A1 (es) 2009-07-01
NI200900170A (es) 2010-09-09
JP2018021046A (ja) 2018-02-08
JP5927241B2 (ja) 2016-06-01
US10385037B2 (en) 2019-08-20
CA2681633A1 (en) 2008-09-25
KR101791757B1 (ko) 2017-10-30
US20120165536A1 (en) 2012-06-28
ES2734253T3 (es) 2019-12-05
CN101679380A (zh) 2010-03-24
MY180812A (en) 2020-12-09
US8153659B2 (en) 2012-04-10
JP2014224118A (ja) 2014-12-04
RU2009138500A (ru) 2011-04-27
US20140073669A1 (en) 2014-03-13
CO6231033A2 (es) 2010-12-20
CL2008000805A1 (es) 2009-05-22
EP3101017B1 (en) 2019-06-12
EP3101017A1 (en) 2016-12-07
CN103641814A (zh) 2014-03-19
US20160024048A1 (en) 2016-01-28
MX2009010082A (es) 2009-10-19
RU2471794C2 (ru) 2013-01-10
ES2601131T3 (es) 2017-02-14
NZ599199A (en) 2013-10-25
CR20140368A (es) 2014-08-25
IL200990A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2009010082A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
PH12014501082B1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
MX2009002666A (es) Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
MY157495A (en) 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
MX2011011136A (es) Eteres diarilicos.
WO2008027542A3 (en) 5-substituted isoindoline compounds
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
MX346608B (es) Compuestos de isoindol 5-sustituidos.
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MX2009006334A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona.
MX2012007217A (es) Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos.
TNSN08369A1 (en) Benzimidazole derivatives
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
IL194390A0 (en) Heterocyclic gaba alpha subtype selective receptor modulators
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.
UA94759C2 (ru) Производные пиразола как ингибиторы цитохрома p450